论文部分内容阅读
目的 探讨替加环素联合头孢哌酮舒巴坦治疗多重耐药鲍曼不动杆菌肺炎的临床疗效,为合理选用抗菌药物提供临床依据.方法 选取2013年1月-2015年3月53例多重耐药鲍曼不动杆菌肺炎患者,随机分为替加环素联合头孢哌酮舒巴坦治疗组27例;头孢哌酮舒巴坦单药治疗组26例,观察两组治疗后临床疗效和细菌学疗效的差异.结果 替加环素联合头孢哌酮舒巴坦治疗组治疗有效率、细菌学清除率分别为81.48％、66.67％,头孢哌酮舒巴坦单药组分别为53.85％、34.61％;联合组在治疗有效率和细菌学疗效方面均显著优于单药治疗组(P＜0.05).结论 替加环素联合头孢哌酮舒巴坦作为治疗多重耐药鲍曼不动杆菌肺炎的给药方案,能取得满意的临床疗效.“,”Objective To study the clinical effect and applicability of cefoperazone sulbactam com bined with tigecycline in treatment of pneumonia caused by multi-drug resistant Acinetobacter baumannii.Methods The data was collected from 80 patients with multi-drug resistant Acinetobacter baumannii pneumonia between January 2013 and March 2015.The patients were divided into the cefoperazone sulbactam combined with tigecycline group (27 cases,group A) and the cefoperazone sulbactam group (26 cases,group B).The clinical efficacy and bacterial clearance rate of these drugs were reviewed,and statistical analysis was performed with SPSS15.0 software.Results The total effective rate of treatment was 81.48％ in group A and 53.85％ in group B.The bacterial clearance rate was 66.67％ in group A and 34.61％ in group B.The difference between group A and group B was statistically significant.Conclusion Cefoperazone sulbactam combined with tigecycline for treatment of multi-drug resistant Acinetobacter baumannii pneumonia is safe,effective,and worthy of clinical application.